Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

As No­vo Nordisk and Pfiz­er dis­close some da­ta on their oral weight loss drugs in Phase III and II, re­spec­tive­ly, Eli Lil­ly is beef­ing up its stance in the obe­si­ty field with three late-stage clin­i­cal tri­als of its next-gen­er­a­tion GLP-1 ag­o­nist or­for­glipron.

The moves, dis­closed in up­dates to the fed­er­al clin­i­cal tri­als data­base this week, put the In­di­anapo­lis drug­mak­er ahead of Pfiz­er, whose sci­ence chief has said the com­pa­ny will “cher­ry-pick” which of its mid-stage can­di­dates to take deep­er in­to the clin­ic af­ter da­ta late this year or ear­ly next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER